PFIZER INC (PFE)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PFE
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PFE | Director; Chair | 53 | ["Chair","Expertise in health care, public policy, and the biopharmaceutical industry","Experience at the U.S. Food and Drug Administration (FDA)","Partner at New Enterprise Associates, Inc.'s Healthcare Investment Team","Senior Fellow of the American Enterprise Institute since 2019","23rd Commissioner of the FDA from 2017 to 2019","Experience on the boards of directors of Tempus AI, Inc. and Xaira Therapeutics, Inc."] | ["Regulatory and Compliance","Science and Technology","Regulatory and Compliance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ILMN | Director | 48 | ["Former FDA Commissioner","Special Partner at New Enterprise Associates","Resident fellow at American Enterprise Institute for Public Policy Research","FDA Deputy Commissioner for Medical and Scientific Affairs","Senior Advisor for Medical Technology to the FDA Commissioner","B.A. in Economics from Wesleyan University","M.D. from Mount Sinai School of Medicine of New York University"] | [] | 2021 |
Biography sourced from the proxy statement filing.
Scott Gottlieb, MD, is a prominent figure in the healthcare and biopharmaceutical industries, currently serving as a Partner on New Enterprise Associates, Inc.'s Healthcare Investment Team and as the Chair of Pfizer Inc.'s board. In 2019, Gottlieb transitioned from his role as the Commissioner of the U.S. Food and Drug Administration (FDA), a position he held from 2017 to 2019, to focus on his work in the private sector. During his tenure at the FDA, he was instrumental in implementing policies that aimed to accelerate the development and approval of new drugs and medical devices, while also strengthening the agency's oversight of the tobacco industry.
At Pfizer, Gottlieb serves as an independent board member, bringing significant expertise in healthcare, public policy, and the biopharmaceutical industry to the company. He chairs the Regulatory and Compliance Committee and is a member of the Science and Technology Committee, where he plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards. His leadership and insights are particularly valuable as Pfizer continues to navigate the complex landscape of global healthcare and pharmaceutical innovation.
Prior to his role at Pfizer and his time at the FDA, Gottlieb was a Venture Partner at New Enterprise Associates, Inc. from 2007 to 2017, where he helped identify and invest in promising healthcare startups. He also serves on the boards of Tempus AI, Inc. and Xaira Therapeutics, Inc., further demonstrating his commitment to advancing healthcare innovation. Gottlieb's diverse experience, from his work in public policy to his involvement in venture capital and corporate governance, positions him as a key influencer in shaping the future of healthcare and pharmaceuticals.